Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CANADIAN 4-TIER RISK-BASED DEVICE CLASSIFICATION SYSTEM

This article was originally published in The Gray Sheet

Executive Summary

CANADIAN 4-TIER RISK-BASED DEVICE CLASSIFICATION SYSTEM under development by the Canadian Medical Devices Bureau, according to bureau staffers. The system would divide medical devices into two groups -- one for in vitro diagnostics and another for all other medical devices -- and would establish four levels of regulatory oversight based on risk assessment for each category.

You may also be interested in...



Canada Seeking Input On Consensus Standard Recognition Draft Policy

Priority review of recognized medical device consensus standards by Canada's Therapeutic Products Programme (TPP) will be given to those addressing issues germane to several types of devices, according to the draft Policy on Recognition and Use of Standards under Canada's Medical Devices Regulation.

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002137

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel